SG11202108283QA - Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist - Google Patents

Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Info

Publication number
SG11202108283QA
SG11202108283QA SG11202108283QA SG11202108283QA SG11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA
Authority
SG
Singapore
Prior art keywords
triazin
imidazo
amine derivatives
tlr7 agonist
tlr7
Prior art date
Application number
SG11202108283QA
Inventor
Guoliang Zhang
Jianzhuang Miao
Changyou Zhou
Gang Chen
Jing Li
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of SG11202108283QA publication Critical patent/SG11202108283QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202108283QA 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist SG11202108283QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019074732 2019-02-07
CN2019098757 2019-07-31
CN2020073673 2020-01-22
PCT/CN2020/074437 WO2020160711A1 (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Publications (1)

Publication Number Publication Date
SG11202108283QA true SG11202108283QA (en) 2021-08-30

Family

ID=71947004

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202108283QA SG11202108283QA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
SG11202108284TA SG11202108284TA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202108284TA SG11202108284TA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Country Status (14)

Country Link
US (2) US12281119B2 (en)
EP (2) EP3921320B1 (en)
JP (2) JP7637328B2 (en)
KR (2) KR20210125026A (en)
CN (2) CN113423708B (en)
AU (2) AU2020218383B2 (en)
BR (2) BR112021015012A2 (en)
CA (2) CA3129178A1 (en)
IL (2) IL285315B2 (en)
MX (2) MX2021009439A (en)
SG (2) SG11202108283QA (en)
TW (2) TWI841679B (en)
WO (2) WO2020160710A1 (en)
ZA (2) ZA202105338B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019262978B2 (en) 2018-05-01 2023-07-13 Revolution Medicines, Inc. C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
WO2019212991A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
BR112021015012A2 (en) 2019-02-07 2021-10-05 Beigene, Ltd. COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF MODULATION OF TLR7, AND METHOD OF TREATMENT OF A DISEASE OR DISORDER IN A PATIENT
CN114206872A (en) * 2019-08-02 2022-03-18 百济神州有限公司 Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists
TW202200589A (en) * 2020-05-28 2022-01-01 瑞士商諾華公司 Mll1 inhibitors and anti-cancer agents
CN114057746B (en) * 2020-08-04 2025-01-28 百济神州(北京)生物科技有限公司 Preparation of imidazo[2,1-F][1,2,4]triazine-4-amine derivatives as TLR7 agonists
CN115119508B (en) * 2021-01-20 2024-05-24 上海维申医药有限公司 Macrocyclic TLR7 agonist, preparation method, pharmaceutical composition and use thereof
WO2022216900A2 (en) * 2021-04-09 2022-10-13 Revolution Medicines, Inc. Synthesis of rapamycin analog compounds
US20240327354A1 (en) * 2021-07-23 2024-10-03 Institut National de la Santé et de la Recherche Médicale Gram-negative bacteria efflux pump inhibitors
JP2025509240A (en) * 2022-03-10 2025-04-11 ナミ セラピューティクス， インコーポレイテッド Formulated and/or co-formulated lipid nanocarrier compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
WO2023230577A1 (en) 2022-05-25 2023-11-30 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
EP2396328A2 (en) 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
BR112012006261B1 (en) 2009-09-21 2021-12-21 Gilead Sciences, Inc ANALOG COMPOUNDS OF 2'-FLUORINE SUBSTITUTED CARBANUCLEOSIDE, USEFUL COMPOUND FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITION AND USE OF ANALOG COMPOUNDS OF 2'-FLUORIDE SUBSTITUTED CARBANUCLEOSIDE
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidines
TW201414737A (en) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 Imidazotriazinecarbonitriles useful as kinase inhibitors
JP5900234B2 (en) 2012-08-09 2016-04-06 ダイキン工業株式会社 Humidifier
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
EP2906563B1 (en) 2012-10-10 2018-02-28 Janssen Sciences Ireland UC Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CN105367576A (en) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 Pyrrolopyrimidine compounds as TLR7 agonists
SG11201701169XA (en) 2014-08-15 2017-03-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine compounds used as tlr7 agonist
EA029789B1 (en) * 2014-12-19 2018-05-31 Янссен Фармацевтика Нв IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kβ INHIBITORS
BR112017024163A2 (en) * 2015-05-12 2018-07-17 Kalyra Pharmaceuticals Inc bicyclic compounds
PL3889145T3 (en) 2015-12-17 2024-07-01 Merck Patent Gmbh 8-cyano-5-piperidine-quinolines as TLR7/8 antagonists and their use in the treatment of immunological disorders
US10138248B2 (en) * 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
CN108069969B (en) 2016-11-11 2020-09-18 南京海璞医药科技有限公司 Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and application
CA3044903A1 (en) 2016-11-28 2018-05-31 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
WO2018210298A1 (en) * 2017-05-18 2018-11-22 江苏恒瑞医药股份有限公司 Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof
BR112021015012A2 (en) 2019-02-07 2021-10-05 Beigene, Ltd. COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF MODULATION OF TLR7, AND METHOD OF TREATMENT OF A DISEASE OR DISORDER IN A PATIENT
CN114206872A (en) 2019-08-02 2022-03-18 百济神州有限公司 Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists

Also Published As

Publication number Publication date
EP3921320A1 (en) 2021-12-15
MX2021009439A (en) 2021-11-12
BR112021015016A2 (en) 2021-10-05
EP3921320B1 (en) 2024-03-06
EP3921320C0 (en) 2024-03-06
EP3921319C0 (en) 2024-03-06
CA3129234A1 (en) 2020-08-13
EP3921319A4 (en) 2022-11-23
IL285315A (en) 2021-09-30
CN113454086B (en) 2025-03-14
CN113423708A (en) 2021-09-21
CA3129178A1 (en) 2020-08-13
KR102853071B1 (en) 2025-09-02
AU2020218383B2 (en) 2024-12-19
IL285311A (en) 2021-09-30
SG11202108284TA (en) 2021-08-30
EP3921319A1 (en) 2021-12-15
TWI841679B (en) 2024-05-11
US20230167117A1 (en) 2023-06-01
ZA202105338B (en) 2022-08-31
IL285315B1 (en) 2025-08-01
AU2020218383A1 (en) 2021-09-02
KR20210125025A (en) 2021-10-15
JP7637328B2 (en) 2025-02-28
ZA202105339B (en) 2023-02-22
TW202045507A (en) 2020-12-16
WO2020160710A1 (en) 2020-08-13
CN113423708B (en) 2025-04-22
MX2021009444A (en) 2021-11-12
TW202045508A (en) 2020-12-16
EP3921319B1 (en) 2024-03-06
TWI835999B (en) 2024-03-21
WO2020160711A1 (en) 2020-08-13
JP2022519374A (en) 2022-03-23
IL285315B2 (en) 2025-12-01
CN113454086A (en) 2021-09-28
AU2020218872A1 (en) 2021-08-26
JP7564112B2 (en) 2024-10-08
KR20210125026A (en) 2021-10-15
BR112021015012A2 (en) 2021-10-05
US20220119394A1 (en) 2022-04-21
US12281119B2 (en) 2025-04-22
JP2022521473A (en) 2022-04-08
EP3921320A4 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
ZA202105338B (en) Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
IL260923B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
IL266305B (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
IL290445B1 (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
ZA201800485B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL290419B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
IL272988A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
IL268923A (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
SG11202108648TA (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
HUE056561T2 (en) Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives
IL280122A (en) Imidazo[1,2-b]pyridazine derivatives as trk inhibitors
IL279156A (en) Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as lox inhibitors
HK40063512A (en) Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
HK40055110A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40055108A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors